Louisiana State University

LSU Digital Commons
LSU Master's Theses

Graduate School

2013

Differential effect of 14 free fatty acids in the expression of
inflammation biomarkers on human coronary arterial cells
Adriana Soto Rodriguez Gil
Louisiana State University and Agricultural and Mechanical College

Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_theses
Part of the Life Sciences Commons

Recommended Citation
Soto Rodriguez Gil, Adriana, "Differential effect of 14 free fatty acids in the expression of inflammation
biomarkers on human coronary arterial cells" (2013). LSU Master's Theses. 4223.
https://digitalcommons.lsu.edu/gradschool_theses/4223

This Thesis is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has
been accepted for inclusion in LSU Master's Theses by an authorized graduate school editor of LSU Digital
Commons. For more information, please contact gradetd@lsu.edu.

DIFFERENTIAL EFFECT OF 14 FREE FATTY ACIDS IN THE EXPRESSION OF
INFLAMMATION BIOMARKERS ON HUMAN CORONARY ARTERIAL CELLS

A Thesis
Submitted to the Graduate Faculty of the
Louisiana State University and
Agricultural and Mechanical College
in partial fulfillment of the
requirements for the degree of
Master of Science
in
The Department of Food Science

by
Adriana Soto Rodriguez Gil
B.S., Zamorano University, 2004
August 2013

This thesis is dedicated to husband Franklin, who supported me every day and motivated me to
never give up.

ii

ACKNOWLEDGEMENTS
It is with my deepest gratitude that I recognize everyone who played an integral role in
the completion of this degree. I would like to first thank God for granting me so many blessings
and opportunities and giving me the strength and wisdom to pursue a research career. To Dr.
John W. Finley, thank you so much for giving me the opportunity to pursue my master’s degree
under your mentorship, for all your advice, support, and for holding me up to high standards.
To Dr. Jack N. Losso, thank you for your constant guidance and support and for always keeping
me motivated. To Dr. Frederick Enright, thank you for your time and advice. I am grateful to
have shared my research with all of you and for all your guidance through my graduate
program. To the LSU AgCenter and Dr. William B. Richardson, for providing the financial support
that allowed the completion of my degree. To Ms. Karen McDonough in the cell culture
laboratory thank you for your continued collaboration in my research. I would also like to thank
all my colleagues in the Foods for Health Research Group and the Food Science faculty and
staff, thank you for enriching my experience at LSU.
To my husband Franklin, thank you for supporting with love my dreams and goals, and
for motivating me to go the extra mile; you helped me believe in myself even in hard times. To
my LSU Food Science, Zamorano Agricultural Society, and Christ the King friends, thanks for
being there for me. To my family, thank you for supporting me and being my cheerleaders, you
have and will always have a special place in my heart.

iii

TABLE OF CONTENTS
ACKNOWLEDGEMENTS ...................................................................................................................iii
ABSTRACT .........................................................................................................................................v
CHAPTER 1. LITERATURE REVIEW ................................................................................................... 1
1.1 INTRODUCTION ................................................................................................................ 1
1.2 REVIEW OF LITERATURE RELEVANT TO THIS APPLICATION ............................................. 2
1.2.1
Atherosclerosis.......................................................................................................... 2
1.2.2
Free Fatty Acids, Inflammation, and CVD ................................................................. 3
1.2.3
Selected Markers of Inflammation ........................................................................... 5
1.2.3.1
Interleukin 6 (IL-6) ............................................................................................. 5
1.2.3.2
Interleukin 8 (IL-8) ............................................................................................. 6
1.2.3.3
Monocyte chemoattractant protein 1 (MCP-1) ................................................ 6
1.2.3.4
Cyclooxygenase 2 (COX-2) ................................................................................. 6
CHAPTER 2. MATERIALS AND METHODS ........................................................................................ 8
2.1 MATERIALS ....................................................................................................................... 8
2.2 PREPARATION OF FATTY ACID SOLUTIONS ...................................................................... 8
2.3 CELL CULTURE .................................................................................................................. 9
2.4 INDUCTION OF INFLAMMATION ...................................................................................... 9
2.5 STATISTICAL ANALYSIS ................................................................................................... 10
CHAPTER 3. RESULTS AND DISCUSSION........................................................................................ 12
CHAPTER 4. CONCLUSIONS AND FUTURE STUDIES ...................................................................... 19
4.1 CONCLUSIONS ................................................................................................................ 19
4.2 FUTURE STUDIES ............................................................................................................ 19
REFERENCES .................................................................................................................................. 21
VITA ............................................................................................................................................... 29

iv

ABSTRACT
Cardiovascular disease is the leading cause of death in the US, and circulating free fatty
acids (FFAs) are known risk factors associated with cardiovascular inflammation. The influence
of 14 dietary FFAs (including saturated, mono-, poly-unsaturated and trans), on the expression
of inflammatory markers in human coronary arterial smooth muscle (HACSM) and endothelial
(HCAEC) cells using a cell culture model was investigated. HACSM and HCAEC cell cultures were
incubated with 200 µM of each FFA for 8 or 24 h respectively at 37 °C in a 5% CO2 humidified
incubator. Inflammatory biomarkers were assessed by ELISA or Western Blot in the supernatant
or cell lysates respectively. Results showed significant differences in the expression of
inflammatory biomarkers among the fatty acid treatments and the control, with myristic and
palmitic acids being identified as the most and linoleic acid as the least pro-inflammatory. This
confirms that FFAs can induce low-grade inflammation in human coronary arterial cells and
provides more information on mode of action.

v

CHAPTER 1
LITERATURE REVIEW
1

1.1 INTRODUCTION
Digestion and absorption of fat primarily involves emulsification and hydrolysis in the
gastrointestinal tract, absorption as free fatty acids or monoglycerides and re-synthesis of new
triglycerides in the liver that are carried as lipoproteins (mainly VLDL and chylomicrons) in the
blood.1 Free fatty acids (FFAs) are released into the bloodstream by the action of hormonesensitive lipase on the adipose tissue or endothelium lipoprotein lipase on circulating
lipoproteins. The FFAs are bound to serum albumin and transported to peripheral tissues. 2-5
Postprandial spikes in dietary fatty acids can occur from 4 to 8 hours after eating occasions. FFA
levels and the time curves in serum are dependent on the fatty acid profile of the meal and the
individual’s daily diet.6,7 FFAs in plasma in healthy adults (fasting-postprandial) range from 350550 μmol/l, but are elevated due to several conditions including obesity (410-730 μmol/l),
insulin resistance (560-570 μmol/l), and type 2 diabetes mellitus (690-770 μmol/l), and can
increase up to 1 mmol/l after a high fat meal.2,8-12 Plasma FFAs are elevated in obese individuals
due to the release of FFAs by the enlarged adipose tissue and consequent reduction of FFA
clearance from the blood; FFA elevation further results in the inhibition of the anti-lipolytic
action of insulin, which increases the FFA release into the bloodstream from chylomicrons and
the adipose tissue.13 Elevation of circulating FFAs has been shown to induce proinflammatory
changes and oxidative stress,14 impair endothelial and vascular function,12 inhibit immune
response,4 and even promote insulin resistance.10 Elevated FFAs are thus now considered an
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indicator of cardiometabolic stress and a risk factor for cardiovascular disease (CVD) 15 including
ischemic heart disease16 and sudden cardiovascular death.17,18
It has been suggested that fatty acid composition of the diet influences the overall
inflammatory state, endothelial function, risk of type 2 diabetes and cardiovascular disease.
Studies have mainly focused on trans fatty acids and indicate that they are directly related to
increased health risks.19-22 However, the mechanism by which not only trans but overall
increased free fatty acids induce inflammation is not well understood. Furthermore, an
assessment of inflammatory response to individual fatty acids has not yet been performed.
The purpose of this study was to evaluate the effect of 14 dietary relevant FFAs
including saturated, mono-, poly-unsaturated and trans, on the expression of inflammation
markers in human coronary arterial smooth muscle (HACSM) and endothelial (HCAEC) cells
using a cell culture model. Evaluation of inflammatory biomarkers in cell culture supernatant as
well as in the cell cytoplasm will allow for a better understanding of the mechanism by which
FFAs promote inflammation and resulting undesirable cardiovascular risks.

1.2 REVIEW OF LITERATURE RELEVANT TO THIS APPLICATION
1.2.1 Atherosclerosis
Cardiovascular disease (CVD) is a group of disorders of the heart and blood vessels and
the number one cause of death in the United States accounting for 25% of US deaths.23-25
Atherosclerosis, a type of of CVD, is a process in which fat, cholesterol, cellular waste, and
calcium build up in the inner lining of an artery forming smooth muscle cell-capped plaque. The
rupture of plaque causes the release of tissue factor and formation blood clots that may block
2

blood flow to the heart, brain, or limbs.26 It is now widely recognized that atherosclerosis is not
a “plumbing” problem, where plaque eventually blocks blood flow by itself. Research has
revealed that atherosclerosis is a process in which proinflammatory stimuli trigger the
expression of adhesion molecules and chemoattractant proteins that allow the infiltration of
leukocytes to the intima and the differentiation of monocytes into macrophages.27,28
Macrophages transform into foam cells by engulfing modified lipoproteins, and the
inflammatory response is amplified by other macrophages and T cells. Eventually, inflammatory
proteins weaken the smooth muscle cell fibrous cap and make it prone to rupture, tissue factor
is released, and a thrombus is formed.27
1.2.2 Free Fatty Acids, Inflammation, and CVD
Research shows that increased circulating free fatty acids (FFA) induce inflammation and
are a risk factor for CVD.12,14,15 Obesity results in elevated plasma FFAs due to the lipolysis of
the enlarged adipose tissue, which results in reduction of FFA clearance from the blood;
additionally, FFA elevation results in the inhibition of the anti-lipolytic action of insulin, which
increases the FFA release into the bloodstream.13 This phenomenon is usually accompanied by
impaired insulin signaling due to increased gluconeogenesis in the liver and reduced glucose
disposal in muscle, which also results in an impaired suppression of insulin-sensitive lipase in
the adipose tissue and impaired removal of FFA from plasma.29,30
An increase in plasma FFA concentrations induces proinflammatory changes and
oxidative stress including an increase in nuclear factor-κB (NF-κB) binding activity and p65
expression without changes in inhibitor κB (IκB) in circulating mono-nuclear cells (MNCs).
Reactive oxygen species (ROS) are generated by MNCs and polymorphonuclear leukocytes
3

(PMNs) from subjects with elevated FFAs.12 An increase in macrophage migration inhibitory
factor (MIF), a proinflammatory cytokine, and an impairment of the endothelium-dependent
flow-mediated vasodilation was also observed as a result of plasma FFA increase.12 Elevation of
FFA in healthy subjects to physiological levels similar to those found in obese individuals results
in the expression of markers characteristic of vascular inflammation (myeloperoxidase),
endothelial activation (ICAM-1, VCAM-1 and E-selectin), and thrombosis (total plasminogen
inhibitor-1).31
In vitro, FFAs (palmitic, oleic, and linoleic) impair nitric oxide production in aortic
endothelial cells by activating IκB kinase-β (IKK-β), which ultimately results in activation of NFκB, as one of the underlying mechanisms of inflammation and endothelial dysfunction. 32
Additionally, treatment of RAW 264.7 macrophage-like cells with saturated fatty acids lauric
and palmitic strongly induced COX-2, iNOS, and IL-1α through the activation of NF-κB through a
possible upstream activation of TLR4. In a similar way, palmitic and stearic acid promote
apoptosis of human coronary endothelial cells through NF-κB activation.33
Early animal studies carried out with dogs and swine showed that increased plasma FFA
may extend the area of coronary ischemia and impair cardiac function due to increased oxygen
requirements for FFA oxidation by the myocardium.34,35 In non-ischemic dogs, myocardial
function and oxygen consumption also increased with increasing FFA uptake although there
were no changes in mechanical activity of the heart.36
Feeding studies have demonstrated that the ingestion of a single high-fat meal
promotes inflammation and endothelial activation by increasing the circulating levels of
inflammatory cytokines TNF-α, IL-6 and IL-17, plasma endotoxin, and adhesion molecules ICAM4

1 and VCAM-1.37-39 A study based on the Nurse’s Health Study also revealed that consumption
of trans fatty acids (18:1 and 18:2) was positively related with plasma levels of soluble TNF-α
receptors, and with levels of IL-6 and CRP in women with high BMI.40
Various authors have identified a relationship between FFA, inflammation and CVD risk.
A study based on the Atherosclerosis Risk in Communities Study showed that FFA levels were
positively associated with an inflammation score quantifying levels of six systemic inflammation
markers (interleukin-6, C-reactive protein, orosomucoid, sialic acid, white cell count, and
fibrinogen).41 Additionally, a study carried out in Paris involving 5250 middle-aged men
identified circulating FFA as an independent risk factor for sudden cardiovascular death (SCD)
mainly attributed to proarrhythmic mechanisms.18 A similar study performed in Germany with
3315 participants also identified elevated FFA as an independent risk factor for SCD. 17 A recent
study carried out in the US has further demonstrated that FFAs positively correlate with insulin
resistance in teens and young adults and with CVD risk factors in older adults, suggesting an
effect of low-grade chronic inflammation.42
1.2.3 Selected Markers of Inflammation
1.2.3.1 Interleukin 6 (IL-6)
Interleukin 6 (IL-6) is a multifunctional cytokine secreted mainly by monocytes but also
produced by many other cells including endothelial and smooth muscle cells. Its functions
include induction of antibody production, and B cell, T cell, and macrophage differentiation.43
IL-6 production is induced by TNF-α and IL-1 through PKC activation or adenylate cyclase, while
being a strong regulator of TNF-α. IL-6 can also regulate the hepatic synthesis of CRP and
promotes atherogenesis by mechanisms including increasing macrophage uptake of lipids.44 Its
5

regulation is controlled by NF-κB and its dysregulation plays a central role in chronic
inflammation including diseases such as obesity and insulin resistance. 45
1.2.3.2 Interleukin 8 (IL-8)
Interleukin 8 (IL-8) is a chemoattractant cytokine (chemokine) that is chemotactic for
lymphocytes, particularly neutrophils, and that plays an important role in inflammation and
angiogenesis.46,47 IL-8 binds to receptors CXCR1 and CXCR2, and in atherogenesis it triggers the
adhesion of monocytes to the vascular endothelium.48 Mechanical stress, hypoxia, and ischemia
may induce the production of IL-8 by cells including leukocytes, endothelial cells, and cardiac
muscle through stimulation by LPS, IL-1, and TNFα.49,50
1.2.3.3 Monocyte chemoattractant protein 1 (MCP-1)
Also a chemokine, monocyte chemoattractant protein-1 (MCP-1) and its receptor (CCR2)
mediate vascular inflammation by potently acting as chemotactic to monocytes.51 MCP-1 is
produced by various types of cells including activated monocytes, lymphocytes, and vascular
endothelial and smooth muscle cells induced by oxidative stress, oxidized fat, and transcription
of NF-κB, AP-1 and Angiotensin II.52,53 MCP-1 is an important mediator in the progression and
destabilization of established atherosclerotic lesions by also triggering the adhesion of
monocytes to the vascular endothelium and promoting the production of tissue factor by
arterial smooth muscle cells.48,53-55
1.2.3.4 Cyclooxygenase 2 (COX-2)
Cyclooxygenase 2 (COX-2) is a bifunctional heme-containing enzyme that catalyzes the
production of PGH2 from arachidonic acid to then form prostaglandins.56 COX-2 expression is
6

exacerbated at sites of inflammation and its synthesis can be up-regulated by pro-inflammatory
stimuli such as tumor promoters and cytokines such as IL-1β through the p38 MAPK
pathway.56,57 PGE2, a prostaglandin derived from the action of COX-2 plays an important role
including the development of the three major hallmarks of inflammation: swelling, pain, and
fever.56 Authors have also suggested a role of COX-2 in the resolution of inflammation through
the production of prostanoids other than PGE2 (such as PGD2 and 15deoxyΔ12-14PGJ2) which bind
and activate peroxisome proliferator activated receptor (PPAR)-γ.56-58
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CHAPTER 2
MATERIALS AND METHODS

2.1 MATERIALS
Fatty acids certified >99% purity (butyric, lauric, myristic, palmitic, stearic, oleic, linoleic,
linolenic, arachidonic, EPA, DHA, elaidic, trans vaccenic, and conjugated linoleic acid) were
purchased from Nu-Chek Prep (Elysian, MN). Sterile Dulbecco’s PBS was purchased from
Invitrogen (Grand Island, NY). Fatty acid free bovine serum albumin (BSA) was obtained from
Sigma-Aldrich (St. Louis, MO). Human Primary Coronary Artery Endothelial (HCAE) and Smooth
Muscle (HCASM) Cell cultures were purchased from ATCC (Manassas, VA). IL-6, IL-8, and MCP-1
ELISA kits were purchased from PeproTech (Rocky Hill, NJ). Goat anti-COX-2 polyclonal antibody
was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Electrophoresis gels and
Western Blot kits (WesternBreeze) were purchased from Invitrogen (Carlsbad, CA). All other
reagents were of analytical grade and obtained from Fisher Scientific (Waltham, MA). Water
was Milli Q (Millipore Corporation, MA) for all the studies.

2.2 PREPARATION OF FATTY ACID SOLUTIONS
Fatty acids were conjugated to BSA based on the methods developed by McIntosh,
Toborek and Henning, and van Greevenbroek el al.59-62 Briefly, for each 1ml of 10 mM solution,
10 μmoles of fatty acid were aseptically weighed in a sterile tube and dissolved in 90 μl hexane
in a laminar flow hood. A 1N KOH solution was then added equimolar to the fatty acid and the
mixture was vortexed for 10 seconds. The salt was dried under nitrogen until it had a white,
chalky appearance. The salt was immediately diluted in 90 μl of warm (<50 °C) distilled
8

deionized water and mixed with 910 μl of a 25% BSA solution (25% BSA in DPBS+HEPES, pH 7.2,
sterile filtered). The pH was checked and adjusted as necessary with 1N KOH. The conjugated
fatty acid solutions were aliquoted, flushed with argon, and frozen at -80 °C. Aliquots of the BSA
solution were stored similarly to be used as control.

Conjugation of all mono- or

polyunsaturated fatty acids was carried out under argon flow. For oxidized solutions the same
procedure was followed except that fatty acid dilution in hexane was followed by a 30 minute
incubation at 80 °C under oxygen.

2.3 CELL CULTURE
HCASM and HCAE cells were grown using Cascade Medium 231 or 200 (Gibco, Portland,
OR), respectively. Cells were fed every other day until 80% confluence and split at 1 to 3 or 1 to
2. Trypsin solution from Cascade was applied to lift the cells; trypsin was then neutralized with
CMF-PBS. Cells were spun down and resuspended at a density of 10,500 cells/cm2 in their
corresponding media using 6-well plates. For the different treatments, cells were incubated at
37 °C and 5% CO2 in a humidified incubator (Sanyo Biomedical, Wood Dale, IL).

2.4 INDUCTION OF INFLAMMATION
Cells were treated with fatty acids at a final concentration of 200 μM in the media. A
BSA control was included in each experiment. BSA never exceeded 0.5% in the media. Cells
were incubated for 8 h (HCAE) or 20 h (HCASM). Following incubation, cell culture supernatant
was removed and analyzed by ELISA for IL-6, IL-8, and MCP-1. Cells were washed once with PBS,
scraped, and treated with RIPA lysis buffer [50 mM Tris-HCLHCl, ph 7.4, 150 mM NaCl, 0.1%
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Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS] supplemented with protease inhibitor
mixture, 1 mM PMSF, and 2mM sodium orthovanadate; followed by incubation at 4 °C for 30
minutes. The cell lysates were then centrifuged at 14,000 xg and 4 °C for 30 min to remove
impurities. Protein concentration in the cytoplasmic extracts was determined with the Bio-Rad
DC Protein Assay Kit (Hercules, CA). Supernatants and lysates were analyzed immediately or
aliquoted and stored at -80 °C until further analyses. Cell viability was assayed using the MTT
CellTiter 96® Non-Radioactive Cell Proliferation Assay from Promega (Madison, WI)
COX-2 was analyzed in selected treatments by Western Blot. Briefly, equal protein levels
(50 μg) of the cytoplasmic extracts were separated using electrophoresis with 12% Bis-Tris gels
and transferring to PVDF membranes. Membranes were blocked with 5% BSA in TPBS
(PBS+Tween 20 at 0.5%), followed by an incubation with primary goat anti COX-2 antibody
1:200 with 5% BSA in TTBS. The bound antibody was visualized by probing with horseradish
peroxidase-conjugated secondary antibody (rabbit anti-goat 1:2000) followed by exposure to
chemiluminescent substrate (SuperSignal West Pico, Thermo Scientific, Rockford, IL) with X-ray
film (Kodak X-omat 1000A processor). Densitometry of Western Blot bands was performed with
Quantity One® 1-D Analysis Software version 4.6.5 (Bio-Rad Laboratories, USA).

2.5 STATISTICAL ANALYSIS
Biomarker levels were normalized based on the non-treated control and adjusted for
cell viability, where biomarker levels for BSA control were set to 1.0. All results are presented as
mean ± SD of triplicate analyses. Statistical analysis was performed using one-way analysis of
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variance (ANOVA). Separation of means was performed by the Tuckey’s Studentized Test (SAS®,
version

9.2).

Differences

were

considered
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statistically

significant

at

P<0.05.

CHAPTER 3
RESULTS AND DISCUSSION

The effect of carbon chain length on levels of inflammatory markers was evident in both
endothelial and smooth muscle cells. As seen in Figure 2.1, levels of IL-6 were directly related
with carbon chain length for fully saturated fatty acids of 4-14 carbons on HCAE and all fatty
acids on HCASM. The longest saturated fatty acids tested on SM, myristic (14:0), palmitic (16:0)
and stearic (18:0), induced IL-6 levels significantly higher than the control. A similar chain length
effect was observed in the levels of IL-8 for fatty acids of 4-14 carbons on HCAE and fatty acids
of 12-16 carbons on HCASM. Palmitic acid (16:0) was the only fatty acid that increased IL-8
levels higher than control on both cell lines. MCP-1 levels also increased with increasing fatty
acid chain length up to 16 carbons, however significant differences from control were only
observed for palmitic acid on HCASM. Interestingly, MCP-1 levels decreased in cells treated
with stearic (18:0) acid, and levels were significantly lower than control in SM cells treated with
saturated fatty acids with 12, 14, and 18 carbons in the main chain. Overall, myristic and
palmitic acid were the most pro-inflammatory of the fully saturated fatty acids.
The effect of cis double bonds on biomarker levels was evident in both cell lines (Figure
2.2). When treated with 18-carbon fatty acids, levels of IL-6 in both cell lines decreased as
amount of double bonds increased from zero to two, and then slightly increased with 3 double
bonds. This slight increase may have been due to oxidation during sample preparation. Levels
of IL-6 decreased in cells treated with 20-carbon fatty acids. These longer unsaturated fatty
acids also exhibited decreases in inflammatory markers with increasing unsaturation from 4 to
5 double bonds, but the effect was only evident in HCAE (Figure 2.2, see A). Similarly, IL-8 levels
12

in HCASM cells decreased with increasing unsaturation only for 20-carbon chain fatty acids
(Figure 2.2, see B). MCP-1 levels in HCASM (Figure 2.2, see B) were equal or lower (18:0, 18:2)
than control for all treatments, with no apparent relation to degree of unsaturation. IL-8 and
MCP-1 levels remained unchanged for all treatments in HCAE (not shown).

Figure 2.1. Effect of fatty acid chain length on levels of IL-6, IL-8, and MCP-1 in HCAE (A) and
HCASM (B) cells. * Treatment is different from control. Different letters indicate differences
between treatments.

Figure 2.2. Effect of fatty acid unsaturation on levels of IL-6, IL-8, and MCP-1 in HCAE (A) and
HCASM (B) cells. * Treatment is different from control. Different letters within treatments
involving fatty acids with the same carbon chain length indicate differences between
treatments.
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The effect of trans double bonds was evaluated in the 18-carbon fatty acids oleic (18:1),
elaidic (18:1 trans 9), and trans vaccenic (18:1 trans 11). Significant increases in IL-6 and MCP-1
levels were observed only in HCASM cells for trans vaccenic and elaidic acid, respectively
(Figure 2.3, see B). All other treatments were not different from the control or from each other
(not shown).
Linoleic acid (18:2) conjugation did not have a clear effect as compared to its nonconjugated counterpart (Figure 2.3). Levels of IL-6 did not differ amongst both forms of linoleic
acid, but were equal or lower than control in both cell lines (Figure 2.3). MCP-1 levels
marginally increased with conjugation in HCASM cells, where MCP-1 for linoleic acid was lower
than control. IL-8 levels remained unchanged for both treatments and cell lines (not shown).
Overall, linoleic acid proved to be the least pro-inflammatory fatty acid on both cell lines.
The effect of fatty acid oxidation on biomarker levels was evaluated using linolenic acid
(18:3) and DHA (22:6), both omega-3 fatty acids (Figure 2.3). Oxidation of linolenic acid did not
result in changes of inflammatory biomarkers on either cell line, as all levels did not differ from
control or from the non-oxidized treatment. In contrast, oxidation of DHA resulted in a
reduction of IL-6 for both cell lines to levels lower than control. Notably, IL-6 levels for HCASM
treated with non-oxidized DHA were significantly higher than control. Levels of MCP-1 in
HCASM did not differ for cells treated with oxidized DHA, as compared to its non-oxidized
counterpart, however the levels were higher than control in both cases. IL-8 levels in both cell
lines treated with DHA and oxidized DHA did not differ from control or from each other (not
shown).
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Figure 2.3. Effect of trans (t) fatty acids, conjugation (CLA), and oxidation (Ox) on levels of IL-6
and MCP-1 in HCAE (A) and HCASM (B) cells. * Treatment is different from control. Different
letters indicate differences between the treatment and its corresponding non-trans, nonconjugated, or non-oxidized counterpart.
COX-2 analysis (Figure 2.4) revealed a stimulation of this biomarker by oxidized linolenic
acid and DHA in HCAE and by palmitic acid in HCASM. No major differences were observed
between oxidized and non-oxidized omega-3 fatty acid treatments, except for HCAE cells
treated with non-oxidized DHA (22:6), which yielded COX-2 levels higher than control. In
contrast, COX-2 levels in HCASM cells treated with DHA or oxidized DHA were consistently
lower than control.
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Figure 2.4. Changes in levels of COX-2 in the cytoplasm of HCAE (A) and HCASM (B) cells as
influenced by treatment with selected fatty acids.
Increases in levels of secreted cytokines may be due to the production of mitochondrial
reactive oxygen species (ROS) deriving from fatty acid β-oxidation in the cells, a phenomenon
previously observed in kidney damage in diabetes.63 Studies have also shown that increased
oxidation of FFAs in aortic endothelial cells without added insulin results in an increase in
production of superoxide in the mitochondria, which in turn activates the proinflammatory
signal cascade and inactivates prostacyclin synthase and eNOS, important antiatherogenic
enzymes.64
Reductions in IL-6 and MCP-1 observed with increasing double bonds in endothelial and
smooth muscle cells (Figure 2.2, see A and B) may be due to reduction in cell activation, as
previously observed in endothelial cells, where a greater number of double bonds (not
necessarily the position of the last double bond) was critical for the greater activity of ω-3 as
compared to ω-6 fatty acids in the inhibition of endothelial activation. This activation refers to
the ability of the cell to promote monocyte migration, and both IL-6 and MCP-1 are important
signaling proteins in this process.65
Table 2.1 illustrates the fatty acid composition of common fats and oils. Although a
breakdown of trans- fatty acids is not shown, naturally occurring trans- fatty acids are present
16

in small amounts in ruminant fats and include trans-vaccenic acid and conjugated linoleic acid
(CLA).66 Partially hydrogenated vegetable oils may contain trans- fatty acids, mainly elaidic acid,
at levels ranging 10-40%.67 Major dietary sources of arachidonic acid (20:4) are meat, poultry,
and game followed by fish and seafood. Dietary sources of EPA (20:5) and DHA (22:6) are
mainly fish and seafood.68 Shellfish fat may contain up to 4.5% arachidonic acid (sea scallops)
21.5% EPA (pacific oyster) and 22.6% DHA (sea scallops). Marine and fresh water fish oils may
also contain up to 3.9% ARA, 13.5% EPA and 21.9% DHA.69
Table 2.1. Fatty acid composition of common fats and oils. Adapted from ISEO, 2006.70
Fatty Acid %
Oil or Fat Butyric
Lauric
Myristic
Palmitic
Stearic
Oleic
Linoleic Linolenic
Beef tallow
Butterfat
Canola
Cocoa butter
Coconut
Corn
Cottonseed
Lard
Olive
Palm kernel
Palm
Peanut
Safﬂower
Soybean
Sunﬂower

4:0

12:0

14:0

16:0

18:0

18:1

18:2

18:3

4

3

3
11

18

19
12
2
34
3
2
3
14
3
3
4
2
2
4
5

43
29
62
34
6
28
19
44
71
15
40
48
13
24
19

3
2
22
3
2
58
54
10
10
2
10
32
78
54
68

1
1
10

47

24
27
4
26
9
11
22
26
13
8
45
11
7
11
7

1
2
48

16
1

Trans FAs
1-8
1-8

1
1
1

7
1

Several studies have shown that plasma fatty acid composition is a good indicator of
and can be modified by the fatty acid composition of the diet. 71-73 Based on the results of our
study, the fatty acids with higher pro-inflammatory potential are myristic and palmitic acids.
Important sources of these fatty acids include coconut and palm kernel oil (myristic) and palm
oil (palmitic). In contrast, the least pro-inflammatory, and perhaps even anti-inflammatory fatty
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acid was linoleic acid, an omega-3 fatty acid which can be found prominently in safflower,
sunflower, corn, cottonseed, and soybean oil. Increased consumption of such oils could
potentially result in reduced cardiovascular risk due to a reduction in inflammatory state.
Studies have also identified hypercholesterolemic effects of myristic, palmitic and lauric acid
and cholesterol lowering effects of linoleic acid.74-76 Changes in plasma cholesterol in addition
to inflammatory effects may further explain how increased FFAs in plasma contribute to an
elevated risk of CVD.

Although the results of our study do not suggest a clear anti-

inflammatory effect of the omega-3 fatty acids EPA and DHA, consumption of foods and oils
rich in EPA and DHA should not be discouraged due to other well documented beneficial
actions that play an important role in cardiovascular health, such as cholesterol-lowering
effects.77
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CHAPTER 4
CONCLUSIONS AND FUTURE STUDIES

4.1 CONCLUSIONS
An in vitro model has been developed and utilized to identify the pro-inflammatory
effect of free fatty acids in human coronary arterial cells. Careful literature review provides
important background information justifying this study. Circulating free fatty acids have been
identified as a risk factor for inflammation and resulting cardiovascular disease. Screening of
various dietary relevant fatty acids in our model allowed for the identification of fatty acids that
can be used to induce inflammation in human coronary arterial cells.
Saturated, unsaturated, trans, and oxidized fatty acids were conjugated to BSA to
simulate physiological conditions. Cells were incubated with fatty acids and inflammation was
assessed mainly through the expression of cytokines and chemokines in the supernatants.
Inflammation increased with increased chain length in fully saturated fatty acids, and decreased
with unsaturation regardless of the position of the last double bond. Trans double bonds or
fatty acid oxidation were not strong predictors of inflammation in our study. The study allowed
us to identify myristic and palmitic acids as pro-inflammatory, while the least pro-inflammatory
and perhaps even anti-inflammatory fatty acid was linoleic acid, an omega-3 fatty.

4.2 FUTURE STUDIES
We propose that a further study is carried out to evaluate the effect of the combination
of fatty acids on the inflammatory response. This experiment could be carried out in a dietary
relevant way, such that the evaluated fatty acid combinations would represent the fatty acid
19

profiles of common fats and oils. Focusing on gene expression could also provide valuable
information as to the mechanism of action of fatty acids in promoting or preventing
inflammation.
The fatty acid-induced inflammation model than we have proposed in this dissertation
could represent a time and cost-efficient approach to explore the anti-inflammatory potential
of foods. Experiments can be carried out in the intervention or prevention approaches to
evaluate the effect of food or their extracted bioactives in modulating fatty acid-induced
inflammation. Due to the widespread availability of palmitic acid in foods, we suggest this fatty
acid be used in the model for future studies.
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